Background: Alzheimer disease is a neurodegenerative disorder that progresses with
marked interindividual clinical variability. We postulate the existence of endogenous …

Background: Alzheimer disease is a neurodegenerative disorder that progresses with
marked interindividual clinical variability. We postulate the existence of endogenous …

Background Since many peptide sequences, including Aβ, are susceptible to amyloid-like
aggregation, there is evolutionary pressure to inhibit deleterious protein misfolding; …

Compelling evidence indicates that aggregation of the amyloid β (Aβ) peptide is a major
underlying molecular culprit in Alzheimer disease. Specifically, soluble oligomers of the 42 …

Background Since peptide sequences other than ß-amyloid are susceptible to aggregation
(the “amylome”), there is evolutionary pressure to inhibit deleterious protein-misfolding; …

Although the formation of β-amyloid (Aβ) deposits in the brain is a hallmark of Alzheimer
disease (AD), the soluble oligomers rather than the mature amyloid fibrils most likely …

Background: The key pathogenic event in the onset of Alzheimer's disease (AD) is believed
to be the aggregation of the β-amyloid peptide (Aβ) into toxic oligomers. Molecules that …

The accumulation of the amyloid-β peptide (Aβ) into amyloid plaques, an essential event in
Alzheimer's disease (AD) pathogenesis, has caused researchers to seek compounds that …

Alzheimer's disease is a devastating degenerative disorder for which there is no cure or
effective treatment. Although the etiology of Alzheimer's disease is not fully understood …

Background Amyloid plaques in the brain are considered the hallmark of Alzheimer's
disease (AD). There has been great interest in the identification of agents which prevent the …